Recent outbreaks of a deadly diarrheal disease in Central America have galvanized national leaders, doctors, nurses and parents, as they battle against the killer disease known as rotavirus. Though it affects rich and poor children alike, the disease causes most of its devastation in developing countries, where rotavirus strikes mainly infants and young children; each year approximately 500,000 children around the world die from the disease.
Sabin/GW Researchers Receive Word on Investigational New Drug Status for Vaccine
NEW CANAAN, CT — Fever, cough, aches and chills mean one thing to most of us as the winter months draw near—influenza, the flu, is circulating again in our community. If we could avoid the misery and potential complications, most of us would choose to do so. Each year, we hope there will be plentiful vaccine, yet once again we have scarce supply.
NEW CANAAN, CT — A global flu outbreak—flu pandemic—strikes three or four times in a century, with a new strain of flu met by weak immune resistance around the globe. The pandemic flu of 1918 killed 40 million people; at least two lesser pandemics occurred in the last half of the 20th century.
Leading experts are available to comment on the science and safety of vaccines, and parents are available to discuss what can happen when parents choose not to immunize their children.
NEW CANAAN, CT— The Cancer Vaccine Consortium (www.sabin.org/cv_consortium.htm) will hold its third semi-annual meeting April 1-2, 2004 in Orlando, Florida, to explore federal regulation of cancer vacci
NEW CANAAN, CT—The Board of Trustees of the Albert B. Sabin Vaccine Institute announced the election of their newest board member, Walter Orenstein, MD. Recently recruited as Professor of Medicine and Pediatrics at Emory University School of Medicine, Dr. Orenstein’s posts at Emory will include director of the Program for Vaccine Policy and Development and associate director of the Vaccine Center. Dr.
NEW CANAAN, CT, November 4, 2003—The Sabin Vaccine Institute, a non-profit research and education organization based in New Canaan, today concluded the second meeting of the Cancer Vaccine Consortium (CVC). The three-day meeting was held in Bethesda, Maryland and drew attendees from the United States, Canada and Europe. The purpose of the CVC is to enhance collaboration among companies undertaking research and development on cancer immunotherapies.
NEW CANAAN, CT—Treatment options for a variety of cancers are expanding to include an array of exciting new approaches. Along with well-established companies, newer biotechnology and biopharmaceutical firms are looking to break into an emerging market that would provide vaccines for both solid cancers—such as melanoma, prostate, breast, lung, cervical, colon, brain, and ovarian—and blood borne cancers—such as lymphoma, leukemia, and myeloma.